Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial

Open access

Abstract

Background The multicentre, international ADDITION-Europe study investigated the effect of promoting intensive treatment of multiple risk factors among people with screen-detected type 2 diabetes over 5 years. Here we report the results of a post-hoc 10-year follow-up analysis of ADDITION-Europe to establish whether differences in treatment and cardiovascular risk factors have been maintained and to assess effects on cardiovascular outcomes.Methods As previously described, general practices from four centres (Denmark, Cambridge [UK], Leicester [UK], and the Netherlands) were randomly assigned by computer-generated list to provide screening followed by routine care of diabetes, or screening followed by intensive multifactorial treatment. Population-based stepwise screening programmes among people aged 40-69 years (50-69 years in the Netherlands), between April, 2001, and December, 2006, identified patients with type 2 diabetes. Allocation was concealed from patients. Following the 5-year follow-up, no attempts were made to maintain differences in treatment between study groups. In this report, we did a post-hoc analysis of cardiovascular and renal outcomes over 10 years following randomisation, including a 5 years post-intervention follow-up. As in the original trial, the primary endpoint was a composite of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation, up to Dec 31, 2014. Analyses were based on the intention-to-treat principle. ADDITION-Europe is registered with ClinicalTrials.gov, NCT00237549.Findings 343 general practices were randomly assigned to routine diabetes care (n=176) or intensive multifactorial treatment (n=167). 317 of these general practices (157 in the routine care group, 161 in the intensive treatment group) included eligible patients between April, 2001, and December, 2006. Of the 3233 individuals with screen-detected diabetes, 3057 agreed to participate (1379 in the routine care group, 1678 in the intensive treatment group), but at the 10-year follow-up 14 were lost to follow-up and 12 withdrew, leaving 3031 to enter 10-year follow-up analysis. Mean duration of follow-up was 9·61 years (SD 2·99). Sustained reductions over 10 years following diagnosis were apparent for bodyweight, HbA 1c, blood pressure, and cholesterol in both study groups, but between-group differences identified at 1 and 5 years were attenuated at the 10-year follow-up. By 10 years, 443 participants had a first cardiovascular event and 465 died. There was no significant difference between groups in the incidence of the primary composite outcome (16·1 per 1000 person-years in the routine care group vs 14·3 per 1000 person-years in the intensive treatment group; hazard ratio [HR] 0·87, 95% CI 0·73-1·04; p=0·14) or all-cause mortality (15·6 vs 14·3 per 1000 person-years; HR 0·90, 0·76-1·07).Interpretation Sustained reductions in glycaemia and related cardiovascular risk factors over 10 years among people with screen-detected diabetes managed in primary care are achievable. The differences in prescribed treatment and cardiovascular risk factors in the 5 years following diagnosis were not maintained at 10 years, and the difference in cardiovascular events and mortality remained non-significant.Funding National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for General Practice, Novo Nordisk, Novo Nordisk Foundation, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, Danish Medical Research Council, Aarhus University Research Foundation, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Wellcome Trust, UK Medical Research Council, UK National Institute for Health Research, UK National Health Service, Merck, Julius Center for Health Sciences and Primary Care, UK Department of Health, and Nuts-OHRA.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30349-3

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 33 references

Research works printed but not linked: 1

  1. Rutten, 1999, Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2, Huisarts Wetensch, 42, 67

Cited by

See all 55

Metadata

Authors
Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Witte, D. R., Lauritzen, T., Sharp, S. J., Dalsgaard, E.-M., Davies, M. J., Irving, G. J., Vos, R. C., Webb, D. R., Wareham, N. J., & Sandbæk, A.
Affiliations
  • University of Cambridge (GB)
  • Utrecht University (NL)
  • University of Leicester (GB)
  • Aarhus University (DK)
Corresponding author
Griffin, Simon J
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-12
Volume
7
Issue
12
Pages
925-937
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2990498790
Cited by
55
References
33
Citations by year
2026: 5 · 2025: 2 · 2024: 12 · 2023: 12 · 2022: 9 · 2021: 9 · 2020: 5 · 2019: 1
FWCI
4.88
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Apollo (University of Cambridge) (submittedVersion, cc-by-nc-nd)
  • Utrecht University Repository (Utrecht University) (submittedVersion)
  • Apollo
Funders
  • Manchester Biomedical Research Centre
  • Medical Research Council (G0001164, MC_UU_12015/1, MC_UU_12015/4)
  • National Institute for Health and Care Research (RP-PG-0606–1272)
  • Novo Nordisk
  • Merck KGaA
  • Programme Grants for Applied Research (RP-PG-0606–1259)
  • Wellcome Trust (G061895)
  • Novo Nordisk Fonden
  • GlaxoSmithKline
  • Bundesamt für Strassen
  • Strategiske Forskningsråd
  • Department of Health, Australian Government
  • Sundhed og Sygdom, Det Frie Forskningsråd
  • Health Technology Assessment Programme (08/116/300)
  • Danmarks Grundforskningsfond
  • Aarhus Universitets Forskningsfond
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, screen-detected diabetes, cardiovascular risk factors, cardiovascular outcomes, cardiovascular mortality, myocardial infarction, stroke, revascularization, amputation, renal outcomes, diabetic nephropathy, microalbuminuria, HbA1c, blood pressure, lipid-lowering therapy, primary care, long-term follow-up
MeSH terms
Adult, Aged, Blood Pressure, Cholesterol, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Europe, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Mass Screening, Middle Aged, Primary Health Care, Treatment Outcome, Guidelines as Topic, Diabetic Cardiomyopathies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(19)30349-3
The paper
Griffin, S. J., Rutten, G. E. H. M., Khunti, K., Witte, D. R., Lauritzen, T., Sharp, S. J., Dalsgaard, E.-M., Davies, M. J., Irving, G. J., Vos, R. C., Webb, D. R., Wareham, N. J., & Sandbæk, A. (2019). Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(19)30349-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.